UCB raises 2026 guidance on strong BIMZELX and CIMZIA demand
FROM THE WIRE · FINANCE.YAHOO.COM
UCB raised its full-year 2026 guidance, now targeting revenue growth in the low 20% range and adjusted EBITDA expansion in the low to mid 40% range, after stronger than expected demand for BIMZELX and CIMZIA. The new outlook suggests UCB is extracting more operating leverage…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishA guidance upgrade from a large Belgian pharma group can support the stock and the European biotech sector.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01UCB raised its full-year 2026 guidance.
- 02It now targets revenue growth in the low 20% range.
- 03Adjusted EBITDA is expected to grow in the low to mid 40% range.
- 04Demand for BIMZELX and CIMZIA was stronger than expected.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets